(Press-News.org) LA JOLLA, CALIF. - March 19, 2021 - Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a drug candidate that blocks the uptake of glutamine, a key food source for many tumors, and slows the growth of melanoma. The drug is a small molecule that targets a glutamine transporter, SLC1A5, which pumps the nutrient into cancer cells--offering a promising new approach for treating melanoma and other cancers. The study was published in the journal Molecular Cancer Therapeutics.
"While great strides have been made recently in the treatment of melanoma, many patients' tumors become resistant to therapy, and this has become a major obstacle in the successful treatment of the disease," says Ze'ev Ronai, Ph.D., director of the National Cancer Institute (NCI)-designated Cancer Center at Sanford Burnham Prebys and senior author of the study. "This study describes a promising compound that selectively targets the uptake of glutamine, an amino acid nutrient that tumors rely on for survival. We are hopeful this drug will fill an unmet medical need for people living with this deadly cancer."
More than 7,000 people die from melanoma each year in the U.S., according to the American Cancer Society, and cases continue to increase annually. In the past decade, immunotherapy and personalized treatments have extended survival times for many patients. However, because of the high incidence of cancer recurrence, scientists are increasingly focused on therapeutic strategies to prevent relapse and increase overall survival.
"This is a very important study because many targeted drugs for melanoma treatment have been significantly hindered by the rapid development of treatment resistance, sometimes as quickly as within several months. While immunotherapy approaches are promising, they are only effective in a subset of patients, and treatment resistance can also develop in this setting as well," says M. Celeste Simon, Ph.D., Arthur H. Rubenstein, MBBCh Professor in the department of Cell and Developmental Biology and scientific director of the Abramson Family Cancer Research Institute at the Perelman School of Medicine at the University of Pennsylvania. "The drug candidate identified in Dr. Ronai's study offers an exciting new therapeutic approach for treating tumors addicted to glutamine, which includes a long list of human cancers, and will hopefully lengthen the amount of time that people with melanoma respond to available treatments."
Blocking the tumor's food supply
Researchers know that rapidly growing tumors are able to reprogram their metabolism to generate extra energy to survive and grow. Tumors often achieve this by pumping increasing levels of the amino acid glutamine into their cells, primarily through a pump called SLC1A5. As a result, cancer researchers are working to find drugs that block SLC1A5 and reduce glutamine levels.
In the study, Ronai and his team set out to identify drug(s) that can inhibit glutamine uptake. Working in collaboration with researchers at the Institute's Conrad Prebys Center for Chemical Genomics, the scientists screened 7,000 diverse compounds for their ability to interfere with SLC1A5. This work identified about 20 hits, or promising options, and one was selected based on its superior ability to prevent SLC1A5 from reaching the cell membrane. This drug candidate, IMD-0354, inhibited tumor growth in both cell culture and in mice with melanoma.
"Our study shows that targeting SLC1A5, which stops glutamine from ever entering the cell in the first place, is an effective way to slow cancer cell growth," says Yongmei Feng, Ph.D., staff scientist in the Ronai lab at Sanford Burnham Prebys and first author of the study. "Because many tumor types are dependent upon glutamine for survival, this drug may be able to treat many different types of cancers."
As a next step, Ronai and his team will further refine IMD-0354, with a focus on improving biophysical properties that will help accelerate preclinical evaluation of the drug candidate.
INFORMATION:
Additional study authors include Gaurav Pathria, Susanne Heynen-Genel, Michael Jackson, Brian James, Jun Yin and David A. Scott of Sanford Burnham Prebys. The study's DOI is 10.1158/1535-7163.MCT-20-0354.
Research reported in this press release was supported by the National Institutes of Health (NIH) (R35CA197465, P30CA030199), the Department of Defense (DoD) (CA1810216), and the Melanoma Research Alliance (509524).
About Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and children's diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us at SBPdiscovery.org or on Facebook at facebook.com/SBPdiscovery and on Twitter @SBPdiscovery.
A more energy-efficient method improves how an industrial gas is purified by reversing the traditional process. The concept was developed and successfully tested by scientists at Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) in Japan and colleagues. The findings were reported in the journal Angewandte Chemie International Edition.
Acetylene is a gas used in many industries, including as a fuel in welding and a chemical building block for materials like plastics, paints, glass and resins. To produce acetylene, it first needs to be purified from carbon dioxide. Traditionally, this is done by passing the acetylene/carbon ...
Colorectal cancer survivors who maintained a stable body weight but lost muscle and developed fatty deposits in their muscles faced a 40 percent higher risk of premature death than patients who avoided both health issues.
"The conventional wisdom has been that colorectal cancer patients should avoid losing or gaining weight during treatment," said Dr. Justin C. Brown, Assistant Professor and Director of the Cancer Metabolism Program at Pennington Biomedical Research Center. "But maintaining your weight does not mean your body composition remains the same. Muscle can ...
COVID-19 vaccines being rolled out in the UK are effective in preventing severe disease, but the extent to which they prevent against infection is still unclear.
First modelling study looking at relaxing control measures (eg, mask wearing, physical distancing, and lockdown measures) and planned vaccination rollout in the UK suggests that vaccination alone may not be enough to prevent the spread of infection - with the R number estimated to be 1.58 even if the vaccine prevents 85% of new infections occurring, after vaccine rollout is complete and all other control measures are removed.
Relaxing control measures is highly likely to lead to another wave of infection, ...
Reporting in the Lancet Psychiatry today, psychologists at the University of Bath highlight that a widely used technique for autism screening is being misused, which may have prevented many people from receiving an autism diagnosis over the past decade.
When individuals with suspected autism are assessed by a GP, a decision to refer them to a specialist for diagnosis is informed by using the Autism Spectrum Quotient. This ten-point scale, known as the 'AQ-10', is an internationally used technique, whereby individuals agree or disagree with statements such as 'I find it difficult to work out people's intentions'. ...
URBANA, Ill. - Opioid use has dramatically increased in the 21st century, especially among young adults. A new study from the University of Illinois provides insights on usage patterns among Illinois high school students to help inform prevention and treatment strategies.
"The societal and personal costs of opioid misuse are massive. There's been a lot of focus on trying to understand how to combat the current epidemic. But we also need to make sure we have good data in order to know how we should apply our efforts," says Allen Barton, assistant professor in the Department of Human Development and Family Studies at U of I and lead author on the study.
The researchers based their study ...
Using molecular dating tools and epidemiological simulations, researchers at University of California San Diego School of Medicine, with colleagues at the University of Arizona and Illumina, Inc., estimate that the SARS-CoV-2 virus was likely circulating undetected for at most two months before the first human cases of COVID-19 were described in Wuhan, China in late-December 2019.
Writing in the March 18, 2021 online issue of Science, they also note that their simulations suggest that the mutating virus dies out naturally more than three-quarters of the time without causing an epidemic.
"Our study was designed to answer the question of how long could SARS-CoV-2 have circulated in China before it was discovered," said senior author Joel O. Wertheim, PhD, associate professor in the ...
PROVIDENCE, R.I. [Brown University] -- In 2018, physicists showed that something interesting happens when two sheets of the nanomaterial graphene are placed on top of each other. When one layer is rotated to a "magic angle" of around 1.1 degrees with respect to the other, the system becomes a superconductor -- meaning it conducts electricity with zero resistance. Even more exciting, there was evidence that it was an unconventional form of superconductivity -- a type that can happen at temperatures well above absolute zero, where most superconducting materials function.
Since the initial discovery, researchers have been working to understand this exotic state of matter. Now, a research ...
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital (NRI) have identified and characterized two regions of DNA required for the proper expression of Mecp2/MECP2 in mice and humans.
These findings, published in Genes & Development, are helping to shed light on the function of these DNA regions and how they could be potential targets for diagnostic and therapeutic interventions for intellectual disabilities such as Rett Syndrome and MECP2 Duplication Syndrome.
Both of these intellectual disabilities are examples of the importance of precise MeCP2 protein levels for proper brain function. A decrease in this protein leads to Rett Syndrome, while an increase in this protein ...
A set of surveys fielded last year found that a large majority of U.S. adults support COVID-19 mitigation measures, including indoor mask wearing, social distancing, and contact tracing, with significant differences across certain groups. The surveys, which followed the same people in April, July, and November 2020, were conducted by a team of researchers at the Johns Hopkins Bloomberg School of Public Health with colleagues at the SNF Agora Institute at Johns Hopkins University.
Overall public support for COVID-19 mitigation measures was strongest in April 2020 with support remaining high in July and November. The November survey found that 79 percent of U.S. adults supported mask wearing, 78 percent supported social distancing, ...
While the drug tamoxifen reduces the risk of developing breast cancer and prevents recurrence, the side-effects cause many women to discontinue their treatment. A study involving researchers at Karolinska Institutet in Stockholm has now found that a much lower dose than the standard produces a good effect with fewer adverse reactions in women who have yet to enter the menopause. The study, which has been published in the Journal of Clinical Oncology, can play a significant role in the treatment of cancer.
The anti-hormone drug tamoxifen has been used for over 40 years to reduce the risk of relapse in women who have been treated for hormone-related ...
